Generation of Reactive Oxygen Species by Mitochondria. by Hernansanz-Agustin, Pablo & Enriquez, José Antonio
antioxidants
Review
Generation of Reactive Oxygen Species by Mitochondria




Enríquez, J.A. Generation of Reactive
Oxygen Species by Mitochondria.
Antioxidants 2021, 10, 415. https://
doi.org/10.3390/antiox10030415
Academic Editor: Petr Ježek
Received: 9 February 2021
Accepted: 1 March 2021
Published: 9 March 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III CNIC, 28029 Madrid, Spain
2 Centro de Investigaciones Biomédica en Red de Fragilidad y Envejecimiento, Saludable-CIBERFES. Av,
Monforte de Lemos, 28029 Madrid, Spain
* Correspondence: pablo.hernansanz@cnic.es (P.H.-A.); jaenriquez@cnic.es (J.A.E.)
Abstract: Reactive oxygen species (ROS) are series of chemical products originated from one or
several electron reductions of oxygen. ROS are involved in physiology and disease and can also be
both cause and consequence of many biological scenarios. Mitochondria are the main source of ROS
in the cell and, particularly, the enzymes in the electron transport chain are the major contributors
to this phenomenon. Here, we comprehensively review the modes by which ROS are produced by
mitochondria at a molecular level of detail, discuss recent advances in the field involving signalling
and disease, and the involvement of supercomplexes in these mechanisms. Given the importance of
mitochondrial ROS, we also provide a schematic guide aimed to help in deciphering the mechanisms
involved in their production in a variety of physiological and pathological settings.
Keywords: mitochondria; ROS; mechanism; signalling; disease; supercomplexes
1. Introduction
All metazoans require oxygen to survive as it is used by the mitochondria to obtain
operational energy. Mitochondria are composed by a double membrane, the inner mito-
chondrial membrane (IMM) and the outer mitochondrial membrane (OMM), which are
separated by the intermembrane space (IMS) and hold the interior of the organelle, the
mitochondrial matrix, isolated form the cytoplasm. These organelles use a panoply of
carbon sources, from catabolic to anabolic pathways, which generate reducing equivalents
useful for the formation of adenosine 5′-triphosphate (ATP). Reducing equivalents, such
as nicotinamide adenine dinucleotide hydrogen (NADH) or flavin adenine dinucleotide
dihydrogen (FADH2), are co-factors in multiple reactions that store electrons derived from
metabolic oxidations [1]. NADH flux independently and act as substrate of mitochon-
drial complex I (CI), which, in turn, reduces ubiquinone to ubiquinol. On the other hand,
FADH2 remains linked to the enzymes that are in contact with the IMM, where they in-
teract with CoQ to recycle their FAD cofactors by reducing ubiquinone to ubiquinol. The
most prominent example of FAD-dependent enzymes in mitochondria is complex II (CII).
Complex III (CIII) oxidizes ubiquinol to reduce cytochrome c, which, subsequently, donates
its electron to complex IV (CIV). Finally, CIV reduces oxygen to water. CI, CIII, and CIV
couple the electron flux to the ejection of H+ across the IMM, creating a H+ electrochemical
gradient (negative and alkaline inside), the proton motive force (∆p). ∆p is used by a fifth
complex, the ATP synthase (CV), to transfer H+ back to the mitochondrial matrix in an
energy-releasing process, which is used to phosphorylate adenosine 5′-diphosphate (ADP)
into ATP. As long as the oxygen consumption matches the phosphorylation of ADP, the
respiration is coupled to ATP synthesis. Complexes from CI to CIV comprise the mito-
chondrial electron transport chain (mETC), which, together with CV, form the oxidative
phosphorylation system (OXPHOS; Figure 1) [1].
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Figure 1. Mitochondrial oxidative phosphorylation system (OXPHOS). The inner mitochondrial membrane (IMM) comprises
five protein complexes, which couple the transfer of electrons to H+ pumping. Charge distribution across the IMM produces
a ∆Ψm, negative inside. Complex I (CI) is normally found inside supercomplexes with complex III (CIII) (supercomplex
I + III2) or CIII+complex IV (CIV) (N-respirasome), a particularly relevant feature for mitochondrial reactive oxygen species
(ROS) production.
∆p is actively generated by the OXPHOS system; therefore, it reflects an active process
of charge separation across the IMM, unlike the plasma membrane in which the charge
separation is carried out by diffusion potential. ∆p can be further decomposed in mito-
chondrial membrane potential (∆Ψm) and pH gradient (∆pHm). ∆Ψm is created by the
difference in charge distribution across the IMM, being positive in the IMS and negative
in the matrix. Similarly, the distribution of H+ across the IMM makes the IMS acidic and
the matrix alkaline. An often-forgotten integral inner membrane protein that contribute to
the H+ gradient is the NAD(P) transhydrogenase or NNT. NNT couples hydride transfer
of reducing the equivalent between NADH and NADP to proton translocation across the
inner mitochondrial membrane at the expenses of ∆p, generating NADPH of the proton
gradient, but can work in reverse to generate ∆p and NADH from NADPH [2]. In addition
to its role in ATP synthesis, the ∆p is utilized by the mitochondria as the driving force to
import proteins, metabolites and to balance the ion fluxes across the IMM. Interestingly,
the movement of ions and charged molecules across the IMM impacts the ∆p.
One of the more relevant ions that cross the IMM is Ca2+. Mitochondrial Ca2+ uptake is
carried out by the inwardly rectifying mitochondrial Ca2+ uniporter (MCU), a highly specific
channel for Ca2+ [3]. Thus, the MCU passes Ca2+ down the electrochemical gradient without
coupling ATP hydrolysis or transport other ions. Mitochondrion Ca2+ extrusion is primarily
carried out by the mitochondrial Na+/Ca2+ exchanger (NCLX) [4,5] in an electrophoretic
process that mediates the extrusion of 3Na+ per 1Ca2+. The activity of NCLX depends on
the Na+ gradient created by the fast acting mitochondrial Na+/H+ exchanger (mNHE),
which parallels Na+ gradient to ∆pHm [6]. In this way, Ca2+ and Na+ homeostasis becomes
engaged to the activity of OXPHOS. Notably, despite the importance of these exchangers
for mitochondrial homeostasis, their molecular identities have remained unknown until
recently [5,7,8], with the exception of the mNHE whose molecular identification remains to
be confirmed.
All organisms are subjected to acute changes in oxygen availability (hyperoxia and
hypoxia, respectively) and both result in the production of reactive oxygen species (ROS).
ROS are most commonly the product of subsequent one-electron reduction of oxygen.
Thus, one electron reduction of oxygen produces superoxide anion (O2•−), which is the
most common first step in all ROS-producing enzymes and a very toxic species. One-
electron reduction of O2•− produces hydrogen peroxide (H2O2), which is the best-known
ROS acting as second messenger, normally due to its ability of reversibly oxidizing thiols
groups on proteins. Subsequent one-electron reduction of H2O2 yields hydroxyl radical
(•OH), which is an extremely harmful ROS that is notoriously involved in toxic reactions,
such as the Fenton reaction. Mitochondrial ROS are involved in numerous physiological
processes [9–15] and also link the progression from tissue homeostasis to disease [16–19].
Very surprisingly, the mechanisms of ROS production in live cells and tissues are poorly
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understood. Yet, thanks to the work on isolated mitochondria, we have a progressively
deeper knowledge of how these organelles produce ROS [20–24].
2. Modes of ROS Production by Mitochondria
Classical experiments with mETC inhibitors pointed to CI and CIII as the major sources
of ROS within the mitochondria and the cell. From a general point of view, potential sites of
ROS production are triggered depending on the respiration substrate, membrane potential
and, if present, the inhibitor used.
Under normal conditions, coupled respiration on glutamate/malate (GM) or pyru-
vate/malate (PM) activates the Krebs cycle enzymes 2-oxoglutarate dehydrogenase (OGDH),
malate dehydrogenase (MDH), and pyruvate dehydrogenase (PDH), and maintains a low
membrane potential as CV is producing ATP. OGDH, PDH, and MDH reduce NAD+ to
NADH, which is, in turn, a substrate of CI. As electrons flow down the mETC they even-
tually reach CIII and CIV. In this situation, the production of ROS is low, but measurable
and is commonly assigned to CI, the outer ubiquinone-binding site of CIII (CIIIo) and
OGDH [22–24] in the so-called forward electron transfer (FET) (Figure 2A). This mode
of ROS production can be exacerbated by ubiquinone-binding site inhibitors of CI, such
as rotenone or piericidin A [25–28], or by inhibitors of the inner ubiquinone-binding site
of CIII (CIIIi), such as antimicyn A [29,30]. On the other hand, to decrease this type of
ROS production, especially after the application of the mentioned compounds, inhibitors
of the flavin site of CI, such as diphenyleneiodonium (DPI; [31,32]), CIIIo blockers, such
as myxothiazol, stigmatellin, or mucidin [33], and OGDH inhibitors, such as succinyl
phosphonate or 3-methyl-2-oxopentanoate [24,34], can be applied.
Succinate is the substrate of the Krebs cycle enzyme succinate dehydrogenase (SDH),
also known as CII. SDH is representative of a variety of FAD dependent enzymes in
the IMM that reduce ubiquinone, such as glyceraldehyde-3-phosphate dehydrogenase
(G3PDH), dihydroorotate dehydrogenase (DHODH), and electron-transferring flavoprotein
(ETF) [35]. When reducing potential is provided by CII, or to a lesser extent by other FAD-
dependent enzymes, mitochondria over reduce ubiquinone and, under conditions of
mitochondrial hyperpolarization (i.e., inactive CV), electrons are able to flow back through
CI, reducing NAD+ into NADH and producing superoxide. This process is known as
reverse electron transfer (RET) (Figure 2B). RET is the mode that produces the largest levels
of ROS [36] and has been observed in both physiological [12,26] and pathophysiological
situations [16,37,38]. Notably, the exact site of ROS production by RET is not yet clear as
some authors propose that it occurs at the flavin site of CI (CIN; [36,39,40]), whereas others
suggest the ubiquinone-binding site of CI (CIQ) plus CIN [41,42] or the iron-sulphur cluster
N2 [43] as the main actors. The investigations of ROS production by RET have used a
variety of commonly used mitochondrial drugs to halt this mechanism: (i) CI inhibitors
such as rotenone, DPI [20,39] or piericidin A [42]; (ii) OXPHOS uncouplers, which are
∆Ψm-disrupting molecules, such as FCCP [12,20,22,44]. As CI inhibitors can impede other
modes of ROS production (see below), it is recommended to not only defining RET by its
sensitivity to CI blockers (e.g., rotenone sensitivity), but also by using OXPHOS uncouplers.
RET can be exacerbated by the incorporation of molecules to increase ∆p [20], such as the
CV inhibitor oligomycin or ATP, and it has been proposed that RET can be modulated
by the activity of NNT as regulator of the NADH concentration [45,46]. Recently, it has
been shown that mice harbouring ND6-P25L mutation in their mitochondrial DNA [47] are
unable to produce rotenone-sensitive RET, though they still display some residual FCCP
sensitivity [48]. Such inability is due to the capacity of CI to enter into its deactive form
in every catalytic cycle, possibly allowing the enzyme to undergo active/deactive (A/D)
transition very rapidly under hypoxia [48]. In addition, residual ROS production under
succinate oxidation may be caused by the CIIIo [23,49].
Antioxidants 2021, 10, 415 4 of 18
Figure 2. ROS production involving respiratory Complex I. (A) Under normal conditions, minimal
amount of mitochondrial ROS are produced, nicotinamide adenine dinucleotide hydrogen (NADH)
is oxidized at a high rate, as well as ubiquinol and 2-oxoglutarate. (B) Under conditions of normal-
to-high ∆Ψm and accumulation of reduced CoQ (or succinate) complex I works in the reverse
mode, producing high rates of ROS. In addition, a few flavin adenine dinucleotide (FAD)-dependent
enzymes have also been shown to contribute to reverse electron transfer (RET).
As commented above, independently of the electron source, CIII is able to produce
ROS upon inhibition with specific molecules. CIIIi inhibitors, such as Antimycin A promote
the accumulation of electrons inside CIII, which reach the CIIIo site, producing superoxide
anion. It is important to note that CIIIo blockers, such as myxothiazol or stigmatellin do
not induce the production of ROS as they render the complex completely oxidized. Indeed,
CIIIo inhibitors block the production of ROS by Antimycin A.
Under specific experimental conditions, when CI and CIII are inhibited and the
concentration of succinate is low, CII can produce ROS at a significant rate (Figure 3). CII
can also operate in forward and reverse modes as it can accept electrons both from succinate
(forward) and ubiquinol (reverse). When working in the reverse mode (Figure 3A), CII
can produce ROS sensitive to the ubiquinone-binding site inhibitor atpenin A5, and to
the flavin-binding inhibitor malonate. However, when working on the forward mode
(Figure 3B), CII can produce ROS that are only sensitive to monate, indicating that the site
of ROS production under both modes is the flavin [49].
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Figure 3. ROS production by Complex II. CII-dependent ROS production has been shown to occur
only when CI and CIII are blocked. (A) When CoQ is highly reduced CII generates atpenin A5-
sensitive ROS in its reverse reaction. (B) The accumulation of succinate promotes malonate-sensitive
ROS in its forward reaction.
To note, ROS production triggered by oxidation of G3P can also be promoted by other
sources, such as CI (RET) and, more scarcely, CIIIo [23,49]. In very specific experimental
conditions, in which CI and CIII are inhibited, DHODH has been shown to produce
ROS through CII and, to a lesser extent, by itself [50]. Moreover, OGDH, branched-chain
2-oxoacid dehydrogenase (BCODH) and pyruvate dehydrogenase (PDH) are potential
sources of ROS under precise experimental conditions (Table 1) [34].
Table 1. Summary of the main ROS sources in mitochondria. Respiratory enzymes are able to produce ROS in forward
and reverse reactions, as well as under specific physiological conditions, such during acute hypoxia. Biological material is
underlined.
Name and Source System Substrate(s)/Conditions Potentiator(s) Inhibitor(s) References
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3. ROS in Acute Hypoxia
Hypoxia is defined as the decreased availability of oxygen in cells and tissues. Low
oxygen levels trigger a series of responses that are related to many physiological and
pathophysiological scenarios [53]. The counterintuitive observation that hypoxia induced
the production of ROS was called the ROS paradox in hypoxia [54,55]. Not surprisingly,
these observations were challenged by some authors [56,57]. The discrepancy was solved
after measuring the kinetics of ROS production during hypoxia and demonstrating that
superoxide production in hypoxia occurs only during the first minutes of hypoxia [27,30].
Thus, the discrepancy relayed in the variable timing at which the ROS measurements were
taken [57]. Nowadays, though the relationship between chronic adaptation to hypoxia and
the production of ROS is still unclear, acute responses to hypoxia is undoubtedly associated
to hypoxic ROS generation [52,58–62].
The mechanism of hypoxic ROS production has been solved recently (Figure 4).
During the first minutes of hypoxia, CI undergoes the active/deactive (A/D) transition,
which consists of a conformational change involving ND3 and other CI subunits. ND3
rearranges to expose its Cys39 [63–66]. A/D transition is a characteristic dormant state
of CI that is not able to perform its enzymatic activity and, therefore, is not able to pump
H+ [27,67]. As CI becomes deactive in acute hypoxia, the mitochondrial matrix acidifies
and the calcium phosphate precipitates in the matrix partially dissolve, liberating free
Ca2+. The rise in matrix [Ca2+] activates the mitochondrial Ca2+/Na+ antiporter (NCLX),
which promotes the entry of Na+ into the mitochondria. Na+ accumulates in the matrix
and interacts with the carbonyl group in the phospholipids of the inner leaflet of the IMM.
The interaction Na+:phospholipid promotes the formation of phospholipid aggregates,
which, in turn, diminish the fluidity of IMM. The decrease in IMM fluidity lowers ubiquinol
transfer between CII and CIII, while the transfer between CI and CIII is preserved as they
are arranged into supercomplexes [68,69]. The decrease in ubiquinol transfer between CII
and CIII promotes the generation of superoxide at the level of CIIIo due to the uncoupling
of the Q cycle. This mechanism highlights the role of Na+ as second messenger, controlling
OXPHOS and hypoxic redox signalling [52].
Figure 4. Mechanism of ROS production in hypoxia. CI-deactivation upon oxygen reduction induce
de acidification of the mitochondrial matrix, the subsequent solubilization of matrix Ca2+ precipitates.
The concomitant elevation of Ca2+ concentration activate the Ca2+/Na+ antiporter (NCLX). This
causes the elevation of Na+ that decrease the inner membrane fluidity affecting the free CoQ diffusion
and increase ROS production by CIII.
Indeed, it has been recently demonstrated that acute inhibition of NCLX ameliorates
metabolic changes in failing hearts [70]. This pathway could be inhibited by pharmacolog-
ical targeting of CI by rotenone or piericidin A, or by genetic ablation of CI subunits. In
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addition, CIIIo blockers, such as myxothiazol, CII inhibitors, such as dimtheylmalonate,
and NCLX inhibitors, such as CGP-37157 prevent ROS production in hypoxia. Conversely,
this pathway can be triggered in normoxia after application of drugs capable of eliminating
the ∆pHm, such as monensin or nigericin. The uncoupler FCCP was unable to inhibit hy-
poxic ROS at low concentrations. However, concentrations higher than 1 µM increased ROS
production in normoxia and exposing FCCP pre-treated cells to hypoxia did not to further
increase ROS production. This observation indicates that the hypoxic ROS pathway was
being activated in normoxia by high concentration of FCCP, which induced acidification of
the mitochondrial matrix [27].
As Na+:phospholipid lowers IMM fluidity and ubiquinone transfer between CII and
CIII, it is possible that this interaction also controls RET by CI. In this way, by decreas-
ing IMM fluidity, mitochondrial Na+ would lower ubiquinone transfer from CII to CI,
restraining superoxide production. Indeed, data from Elrod’s laboratory showed that
overexpression of NCLX in mouse heart decreases infarct size and ROS production in
ischemia/reperfusion [71], a well-established model of RET in pathophysiology [16]. Thus,
increasing mitochondrial Na+ would not only increase ROS by CIIIo, but also decrease ROS
by CI-RET. This poises mitochondrial Na+ as a modulator of mitochondrial redox signals by
selecting the kind of mechanism to be triggered, the location of superoxide production and
respiratory complex involved. This may be of particular importance as the downstream
adaptative signals triggered by each mechanism could be different, determining the cell
fate as shown in flies [38].
It remains to be understood why in isolated mitochondria ROS levels are proportional
to the environmental oxygen concentration [72–74]. In the past, this summed up to the ar-
guments against the defenders of the ROS paradox [22]. The fact that the production of ROS
does not increase and, rather, decreases with lower oxygen concentration in experiments
with isolated mitochondria, whereas it increases in cells and tissues where cellular and
molecular integrity are better preserved, provides evidence that key elements are missing
or disrupted in experiments with isolated mitochondria. Such discrepancy may be due to
several factors. First, it may be that the procedure of extracting mitochondria disrupts the
native conformation of the oxygen sensor or the integrity of the oxygen sensing machinery
(i.e., calcium phosphate precipitates may partially dissolve in the extraction procedure).
Second, it is also possible that the reaction buffers used with isolated mitochondria do not
resemble the cytosolic composition. In this respect, routinely used respiration buffers do
not contain neither Na+ nor Ca2+, which are essential components for hypoxic induced
ROS production (e.g., extracellular Ca2+ was shown to be essential in order to increase
the magnitude of ROS production), and normally do not use a mixture of substrates (e.g.,
glutamate, malate plus succinate), which are also involved. Third, as the molecular identity
of the oxygen sensor is not known, it is possible that it would be an extramitochondrial
component that becomes lost in the mitochondrial isolation procedure.
In summary, though there is still a need to clarify why isolated mitochondria do not
increase ROS upon hypoxia, it is now clear that low oxygen levels increase the production
of ROS in cells and tissues. In particular, it involves the management of mitochondrial
Na+ through an unexpected interaction with phospholipids, which is, in turn, potentially
implied in all those scenarios in which the hypoxic response, mitochondrial Ca2+ handling,
and/or ROS are involved. In this aspect, finding proteins able to control IMM fluidity may
be also of great importance as they may become potential targets to lower mitochondrial
ROS production and control supercomplex-independent respiration.
4. The Production of ROS and Supercomplexes
As mentioned above, electron transfer between CI and CIII was less sensitive to
Na+:phospholipid interaction than electron transfer between CII and CIII. Given that
CI+CIII activity reflects mostly the activity of supercomplex I+III2 and that CII is not su-
perassembled with CIII at significant proportions [1], it becomes clear that supercomplexes
are not influenced by Na+ signalling [27]. This feature may be important to prevent a
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potentially harmful decrease in respiratory activity at the time a redox signal is delivered.
On the other hand, the more plausible molecular mechanism by which this happens would
be the existence of a functionally partial segmentation of the CoQ pool [1,69,75].
The assembly of CI, CIII, and CIV in supercomplexes confers novel properties to the
electron transport chain. Thus, it allows the partial functional segmentation of the CoQ and
cyt c pools [69,75], stabilize CI and regulate its degradation [26,76–78]. Though the role in
CoQ and cyt c functional segmentation was initially questioned [79–82], recent kinetic and
structural data have confirmed it [68,83–85].
The existence of differentiated CoQ and cyt c redox kinetics between superassembled
and free complexes explain the concept of functional pools generated by the formation
of the supercomplexes. This has immediate consequences on the production of ROS. In
a pioneering work, CI was maintained in supercomplex forming I + III2 or separated
into their individual complexes (I and III2) with detergents. These experiments were
complemented by generation of liposomes reconstituted with purified CI and CIII with
variable phospholipid:protein ratio to either maintain them separated or to allow the
formation of SC I + III2 [86]. Then, the production of ROS by CI was assessed in both
experimental set ups. In either model, the authors found that superassembly of respiratory
complexes reduced the production of ROS [86]. This conclusion was corroborated in vivo
comparing neurons, where mitochondrial complex I is predominantly assembled into
supercomplexes, with astrocytes, that maintain a higher proportion of free complex I. Thus,
astrocyte ROS production is several folds higher than that of neurons [87].
The interaction of complexes III and IV to form the N-respirasome (I + III2 + IV1–2)
or the Q-respirasome (III2 + IV1–2) was also proposed to minimize ROS production from
indirect observations in vivo in zebrafish [83] and in a murine model of heteroplasmy [88],
indicating that the expression of supercomplex assembly factor 1 (SCAF-1; [69,83,89])
reduced ROS levels. A direct demonstration of the impact of the tight interaction between
complexes III and IV in minimizing ROS production was recently provided by the analysis
of partially purified N-respirasomes harbouring or lacking SCAF1 [68]. The presence of
SCAF1 determine the tight interaction of CIV and CIII within the N-respirasome, while
in its absence CIII and CIV are independently attached to CI [68]. Thus, SCAF1 deficient
N-respirasomes were one order of magnitude less efficient in NADH oxidation and in
NADH-dependent oxygen consumption, while they generate significantly more ROS [68].
Therefore, superassembly increases the efficiency of respiration while minimizing ROS
production.
Having stablished the impact of superassembly in ROS production, several mecha-
nistic questions remain to be answered. For instance, it is yet unclear whether the partial
segmentation of the CoQ and cyt c pools is: (1) just a consequence of the proximity of
the CI and CIII, and CIII and CIV catalytic sites; (2) or if it is a combination of this prox-
imity and the specific composition of protein and/or phospholipids in the supercomplex
microenvironment, which may induce a different partitioning of the substrate carriers
between the supercomplex phospholipid environment and that of the IMM. In addition,
it remains unexplored whether superassembly impacts on different mechanisms of ROS
production, such as RET. Nevertheless, factors influencing superassembly could arise as
potential targets for diseases in which ROS are involved.
5. ROS, Acute Oxygen Sensing, and Calcium Homeostasis
Sudden exposure to hypoxia promotes organismal adaptative responses, such as
hyperventilation or systemic vasodilation which are driven by an arterial chemoreceptor,
called carotid body (CB). In particular, the sensory elements in the CB are the glomus cells.
Similarly, the pulmonary vasoconstriction (PV) represents other acute response to hypoxia.
PV is mediated by pulmonary aortic smooth muscle cells (PASMCs). It has been proposed
that a specific CIV subunit, Cox4i2 is essential for oxygen sensing in both cell types [90–92].
This subunit decreases the affinity of CIV for oxygen, rendering more sensitive to variations
in environmental oxygen.
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Interestingly, the interpretation regarding the oxygen sensing mechanism differs in
both systems. On one hand, PASMCs hypoxic mitochondrial hyperpolarization would be a
prerequisite to superoxide release by CIII, which, through the over-reduction of upstream
mETC components, promoted ROS production by uncoupling of the Q-cycle at the level
of CIII [91–93]. On the other hand, ROS mediated oxygen sensing in glomus cells require
CI [59]. Thus, in glomus cells oxygen sensing would be mediated by the accumulation of
ubiquinol followed by RET at CI. This accumulation of ubiquinol would be caused by the
reduced oxygen affinity of CIV in the presence of Cox4i2 [58,90].
As mitochondrial hyperpolarization has been postulated as a necessary factor for
hypoxic ROS production in PASMCs, further experiments with OXPHOS uncouplers,
such as FCCP, measuring ROS in hypoxia would definitely corroborate its involvement
(Table 1). In this regard, the use of OXPHOS uncouplers would also be a valuable tool to
investigate whether RET is indeed the mechanism underlying ROS production in glomus
cells (Table 1). Some other considerations may help to progress in the understanding of the
precise mechanism of ROS production in acute oxygen sensing by these specialized cell
types. CI activity has been shown essential for ROS production and hypoxic pulmonary
vasoconstriction (HPV) in PASMCs [24,93]; thus, given that CII can also feed electrons to
CIII and both are necessary for HPV [94], it is possible that CI is involved in ROS production
by A/D transition. In addition, it was shown that 2, 4-dinitrophenol (DNP), an OXPHOS
uncoupler, or FCCP promoted a biphasic response in HPV; whereas lower amounts had
from mild(increase)-to-no effects on HPV, higher concentrations inhibited it. The former
was attributed to a sustained vasoconstriction during normoxia, which mimicked the effect
of HPV [94]. As mentioned above, OXPHOS uncouplers can activate Na+-hypoxia ROS
mechanism in normoxia. Thus, it is possible that the mimicking effect of DNP is due to
the normoxic activation of this pathway, which, in turn, could not be further activated in
hypoxia due to the presence of the uncoupler (see above, discussion on FCCP and hypoxic
ROS production). This hypothesis is supported by results showing that the steady-state
contraction of HPV could be inhibited by NCLX blockade [52]. The latter may be explained
on behalf of the effect of high concentrations of OXPHOS uncouplers, which can result in
cell toxicity, loss of function and cell death. However, it remains to be elucidated whether
this effect is due to inhibition of RET or to another ROS-unrelated effect.
Of note, a reduced CIV turnover (i.e., CIV in the presence of Cox4i2) would immedi-
ately translate into decreased H+ pumping by the mETC, which, at the same rate of CV
activity, would lead to mitochondrial depolarization (and not to hyperpolarization, as it
has been consistently observed). Therefore, it is possible that either CV turnover decreases,
ATP/ADP ratio augments, or there are other factors involved in ∆Ψm regulation during
acute hypoxia in PASMCs, which have a larger impact on ∆p than that of Cox4i2-driven CIV
brake. However, it has been shown that the ATP/ADP ratio actually decreases during acute
hypoxia in PASMCs [95] and that high ADP inhibits hypoxic response in glomus cells [96].
Alternatively, it is possible that such hyperpolarization, given its rapid occurrence, is a
consequence of the activation of the fast-acting mNHE [97], which would immediately
transform the ∆pHm into ∆Ψm, enabling RET, as long as there was sufficient ubiquinol
accumulation. Activation of mNHE, in turn, would drive to mitochondrial matrix acidifi-
cation, which would promote liberation of free Ca2+, activation of NCLX, mitochondrial
Na+ overload and ROS production. Whether the latter pathway occurs in specialized cells
would depend on the sensitivity to OXPHOS uncouplers to test RET (Table 1), the steady
state of the calcium phosphate precipitates, NCLX expression/activity and the presence of
other factors (e.g., proteins, phospholipids, etc.) regulating IMM fluidity. Nevertheless, to
test whether it occurs and is triggered in PASMCs and/or glomus cells, monensin can be
applied during normoxia (Table 1), as it would activate the hypoxic pathway. It is worth
to mention that in very specific conditions and as mNHE is a reversible antiporter, it is
possible that it itself exerts the exit and entry pathways of Na+, which would, in turn, de-
pend on the Na+ and H+ gradients; rendering Na+ accumulation in hypoxic mitochondria
independent of NCLX.
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Downstream targets of ROS during acute hypoxia include K+ channels and Ca2+
channels. Whereas in some cell types, the main source of Ca2+ has been shown to be the
extracellular milieu, in others it has been proposed to be the sarcoplasmic reticulum (SR).
Such differences in the Ca2+ sources during acute hypoxia probably reflect the dissimilar
composition of Ca2+ channels dedicated to the specific functions of each cell type. Thus,
from a common source of ROS, which is the mETC, several targets can be modified,
regardless of whether they are topologically found in the SR or the plasma membrane,
which, in turn, highlights the pleiotropy of ROS as second messengers in different cell
types.
6. Mitochondrial ROS Production in (Patho)Physiology
Mitochondrial ROS and hypoxia have been involved in the onset and progression
of many physiological and pathophysiological settings, ranging from adaptation to hy-
poxia [52,55,58,59,90–92], regulation of autophagy [96,98], immunity [99–102], differen-
tiation [103,104] to cancer [18], cardiovascular diseases [16], or neurodegenerative dis-
eases [17].
The dysregulation of mitochondrial ROS production has been associated with cancer.
Thus, regulation of ERK MAPK signalling pathway by CIII-dependent ROS is required
for Kras-induced anchorage-independent growth and tumorigenesis [105]. Loss of SdhB
subunit of CII triggers an increase in ROS production and activation of hypoxic inducible
factor (HIF)-dependent genes, promoting tumorigenesis [106]. In addition, metastatic
progression, which is associated with metabolic reprogramming of the cancer cells and
poor outcome, is promoted by mitochondrial ROS [107]. Thus, enhancing mitochondrial
antioxidant capacity may be a rational cancer therapeutic approach. Indeed, targeting
catalase to the mitochondrial matrix of tumour cells suppressed tumour progression and
metastasis in invasive breast cancer in mice [108].
Mitochondrial ROS are related to cardiovascular diseases at different levels. CI RET-
dependent ROS production has been involved in ischemia-reperfusion (I/R) injury [16,37,38].
As there are several features determining superoxide production by RET, this has allowed
the determination of strategies to inhibit ROS-derived RET and injury. For instance,
a therapeutic approach was attempted by clamping CI in its deactive state, and, thus,
uncapable to do RET, with Mito-SNO, a nitrosylating agent capable of modifying Cys39
of ND3 subunit [109]. Similarly, a missense mutant mouse for the mtDNA encoded CI
subunit ND6 in mouse to rapidly undergo A/D transition, showing a significant reduction
on RET and a concomitant protection against I/R injury [48]. It has been also shown
that mice lacking NCLX have increased ROS production during reperfusion and that its
overexpression leads to cardio-protection [71]. The molecular pathways leading to injury
in mice lacking NCLX are related to increased mitochondrial Ca2+ overload and, probably,
to increased superoxide by RET since the main mitochondrial Ca2+ efflux pathway is not
present and mitochondrial Na+ does not slow down ubiquinone transfer from CII to CI. In
this way, the knowledge of the molecular mechanism governing ROS production in this
pathological scenario has led to the opportunity to develop strategies for the treatment of
this disease. Heart failure has been associated to increased ROS production by mitochondria
as well. However, the molecular mechanism does not only involve the mETC. Increasing
mitochondrial Ca2+ levels in failing myocytes promoted higher turnover of dehydrogenases
in the Krebs cycle and production of NADH, which, through the action of NNT, is converted
to NADPH, a key molecule in the buffer of oxidative stress. Importantly, lowering the
levels of mitochondrial Ca2+ lead to decreased NADPH and higher H2O2 (not superoxide)
levels [110,111]. These examples also highlight the importance of an accurate and specific
detection of mitochondrial ROS and that increases in H2O2 do not necessarily arise from
increases in superoxide, though they are interconnected species.
Mitochondrial ROS have also been associated to neurological disorders. Ca2+ home-
ostasis is critical for neuronal work and homeostasis. Engagement of plasma membrane
L-type Ca2+ channels during normal autonomous pacemaking in substantia nigra dopamin-
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ergic neurons promoted transient mitochondrial ROS production and vulnerability to injury
in Parkinson’s disease (PD) development. This was accompanied by mild mitochondrial
depolarization, which was, in turn, partially reversed by antagonists of mitochondrial
uncoupling proteins [17]. Partial depolarization is known to affect NCLX activity [112],
posing NCLX as a possible cause of ROS production in PD. Indeed, halt in NCLX activity
has been associated with increased mitochondrial Ca2+ content and neuronal cell death in
two PD-associated risk protein pathways [113,114]. As hypoxic ROS may be involved in
PD progression, it would be expected that HIF-1α stabilizes during PD. PINK1 knock-out
neurons showed increased levels of mitochondrial ROS and HIF-1α stabilization, which, in
turn, led to a glycolytic switch [115]. It is possible that mitochondrial ROS-driven glycolytic
switch reprograms neuron metabolism in such a way that the production of energy through
glycolysis does not match the high energetic demands of the neuron, thus, facilitating its
entry into apoptosis. Interestingly, modulation of CI has been associated with development
of both PD and Alzheimer’s disease (AD; [116–118]). Given that CI can undergo activation
and deactivation, and both are related to different modes of ROS production, it would be
important to ascertain whether the different physiological states of CI are related to the
pathogenesis in neurological disorders.
Mitochondrial diseases are a form of rare diseases very well defined genetically,
but very difficult to treat as their symptomatic manifestations varies greatly with the
individuals. It was shown that a mice model of mitochondrial disease extended survival
and several other parameters upon exposure to chronic hypoxia [74]. The protection was
shown to be independent to the HIF pathway and, interestingly, brain hyperoxia and ROS
production, were related to brain damage [74].
In all the previous scenarios, the immune system may play a key role and mitochon-
drial ROS are also crucial for its proper function. Mitochondrial ROS production is activated
by the ROS-triggered CII phosphorylation by Fgr tyrosine kinase [119]. This mechanism
drives macrophage activation promoting antibacterial defense [120]. The increase in suc-
cinate oxidation causes ROS production by CI-RET and favors inflammation [12]. Very
interestingly, blocking CII phosphorylation by Fgr tyrosine kinase or overexpression of
catalase in macrophage mitochondrial matrix prevent high fat diet-induced inflammation
and obesity [9]. These works highlight the importance of metabolic rewiring of mitochon-
dria in macrophages, from ATP-forming to ROS-producing, to promote a pro-inflammatory
state.
In all these settings, different mitochondrial ROS mechanisms may play a role. It is
worth to mention that the source of ROS and the mechanism implied can affect greatly what
molecular pathway becomes activated downstream. In this regard, ROS target proteins
differ when CI or CIII was employed as the source of ROS (PMID: 25451644). In this regard,
mitochondrial ROS induced by CI-RET, but not other sources, were able to induce an
increase in lifespan in flies (PMID: 27076081). Thus, it is possible that antioxidant treatment
may not be as effective as expected since it tackles both beneficial and deleterious ROS [121].
Thus, given the relevance of mitochondrial ROS in so many scenarios it is essential to
understand the mechanisms by which they are produced, as it would provide valuable
tools to study and treat an array of diseases. Surprisingly, however, the ways of ROS
production by mitochondria in vivo are poorly understood. To date there are only a few
cases in physiology and disease in which the molecular mechanism of mitochondrial ROS
production is clear [12,16,52]. In this regard, the importance of succinate accumulation, Na+
homeostasis or supercomplex formation are a few examples of possible factors modulating
ROS production by mitochondria in vivo. We propose a simplified workflow, involving a
variety of drugs, to evaluate the mechanisms of ROS production, which may be implied in
specific experimental settings (Figure 5).
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Figure 5. Proposed workflow to evaluate the mechanism of mitochondrial ROS production in cell culture and/or ex vivo.
FET (CI) stands for forward electron transfer at the level of CI, FET (Qo site) stands for forward electron transfer at the
level of Qo site, RET stands for reverse electron transport, CII-derived ROS stands for ROS production at the level of CII,
TCA cycle DH-ROS stands for ROS produced by dehydrogenases at the TCA cycle and Na+-derived ROS stands for ROS
produced by Na+:phospholipid interaction.
With the Figure 5 chart we aim to make the study of ROS production by mitochondria
easier. It should be noted, however, that this workflow should ideally be accompanied
by the corresponding enzymatic activity of the complex involved, in order to discern
whether the complex involved in ROS production is a specific target of the experimental
setting or compound under study. The advantage of this approach is that it can be used
both in isolated mitochondria and cell culture, as well as in tissue culture. Therefore, the
investigator can choose whether the structural and functional integrity of mitochondria
and cells remains closer to their native environment.
With the tools and hypotheses provided herein, we hope that the study of mito-
chondrial ROS production, in any (patho)physiological setting, becomes easier for the
researchers interested in mitochondrial redox biology.
7. Concluding Remarks
Mitochondrial ROS, once considered toxic byproducts of the respiratory activity of
the electron transport chain that need to be eliminated at all cost, are today considered
critical signalling molecules playing a fundamental role in maintaining health. In addition,
the general definition of ROS species is revealingly misleading, since different ROS, like
superoxide or hydrogen peroxide, exert their specific functions in different manners. More-
over, the timing and the specific loci where ROS are generated seems to exert very different
physiological impact. An explosive advance in the development of this scientific field in
the near future is, therefore, expected.
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